Getting Biopharmaceutical Tech Transfer Right the First Time

Publication
Article
BioPharm InternationalBioPharm International-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s27-s31

Good project management, budgeting, planning, and clear documentation are the only ways to prevent overruns and project failure.

Biopharmaceutical experts Stephen Perry, CEO of Kymanox, James Blackwell, principal consultant with The Windshire Group, and consultant Mike Ultee, share best practices and musts to avoid in biopharmaceutical technology transfer.  Some crucial takeaways?  Share all data (especially data on failed runs in the past), and include clear instructions for sampling.  In addition, aim for reproducibility.

 

Download BioPharm International's

2017 Outsourcing Resources eBook

.

 

 

 

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.